Skip to content
lifestyle.briefmobile.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
ELI LILLY AND COMPANY
Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
May 5, 2026
Lilly’s EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis
May 5, 2026
Lilly’s triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes
May 3, 2026
Lilly’s EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis
May 3, 2026
Lilly’s oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet
April 30, 2026
Patients with Crohn’s disease maintained steroid-free remission for three years with Lilly’s Omvoh (mirikizumab-mrkz)
April 29, 2026
Lilly to participate in TD Cowen’s 46th Annual Health Care Conference
April 28, 2026
USOPC Announces the Team USA Athlete Recovery Program in Partnership with Eli Lilly and Company
April 28, 2026
Lilly’s Retevmo (selpercatinib) delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancer
April 28, 2026
ACHIEVE-4, the longest Phase 3 study of Lilly’s Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health
April 17, 2026
←
Previous Page
1
2
3
4
5
6
Next Page
→